Clinical Trial to Assess the Efficacy and Safety of Cicle... | NCT00790023

Label	Type	Description	Intervention Names
80 mcg Ciclesonide	Experimental	80 mcg Ciclesonide once daily	Drug: 80 mcg Ciclesonide
160 mcg Ciclesonide	Experimental	160 mcg Ciclesonide once daily	Drug: 160 mcg Ciclesonide
Placebo	Placebo Comparator	Placebo once daily	Drug: Placebo

Name	Type	Description	Arm Group Labels	Other Names
80 mcg Ciclesonide	Drug	80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)	80 mcg Ciclesonide

Measure	Description	Time Frame
Change From Baseline in Daily Subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Averaged Over the Two-week Treatment Period.	TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent = mild = moderate = severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.	Week 0-2

Measure	Description	Time Frame
Change From Baseline in Daily Subject-reported AM and PM iTNSS Averaged Over the Two-week Treatment Period.	TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent = mild = moderate = severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Give written informed consent, including privacy authorization as well as adherence to concomitant medication withholding periods, prior to participation.
Male or female 12 years and older, as of the Screening Visit (Visit 1).
Subject must be in general good health (defined as the absence of any clinically relevant abnormalities as determined by the Investigator) based on screening physical examination, medical history, and clinical laboratory values (Hematology, Chemistries and Urinalysis).
A history of SAR to Mountain Cedar for a minimum of two years immediately preceding the study Screening Visit (Visit 1). The SAR must have been of sufficient severity to have required treatment (either continuous or intermittent) in the past and in the Investigator's judgment (through exposure to allergen) is expected to require treatment throughout the entire study period.
A demonstrated sensitivity to Mountain Cedar known to induce SAR through a standard skin prick test administered at Visit 1 (screening). A positive test is defined as a wheal diameter at least 5 mm larger than the control wheal (normal saline) for the skin prick test.
Subject, if female 65 years of age or younger, must have a negative serum pregnancy test (performed at Visit 1) prior to randomization at Visit 2. Women of childbearing potential (excluding females at least two years postmenopausal or surgically sterile) must sign the Women of Childbearing Potential Addendum to the informed consent form. Females of childbearing potential must be instructed to and agree to avoid pregnancy during the study and must use an acceptable method of birth control:
1. An oral contraceptive, an intrauterine device (IUD), implantable contraceptive, transdermal or injectable contraceptive for at least 1 month prior to entering the study and will continue its use throughout the study and for thirty days following study participation.
2. Barrier method of contraception, eg, condom and/or diaphragm with spermicide while participating in the study.
3. Abstinence.
Subject or parent/guardian must possess an educational level and degree of understanding of English that enables them to communicate suitably with the Investigator and study coordinator as well as accurately complete both the AR diary and RQLQ(S).

Exclusion Criteria:

Female subject who is pregnant or lactating.
History of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations; recent nasal biopsy; nasal trauma; nasal ulcers or perforations; or surgery and atrophic rhinitis or rhinitis medicamentosa (all within the last 60 days prior to the Screening Visit).
Participation in any investigational drug trial within the 30 days preceding the Screening Visit (Visit 1) or planned participation in another investigational drug trial at any time during this trial.
A known hypersensitivity to any corticosteroid or any of the excipients in the formulation of ciclesonide.
History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, chronic sinusitis, influenza, severe acute respiratory syndrome (SARS)] within the 14 days preceding the Screening Visit (Visit 1).
History of alcohol or drug abuse (or a positive urine drug screen at Visit 1) within two years preceding the Screening Visit.
History of a positive test for HIV, hepatitis B or hepatitis C.
Plans to travel outside the study area (the known pollen area for the investigative site) for more than 24 hours during the Run in period.
Plans to travel outside the study area (the known pollen area for the investigative site) for 2 or more consecutive days between Randomization Visit (Visit 3) and the final Treatment Visit (Visit 5).
Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of beta agonists and any controller drugs (e.g., theophylline, leukotriene antagonists, etc.); intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists is acceptable.
Use of any prohibited concomitant medications within the prescribed (per protocol) time period prior to the Screening Visit and expected use during treatment period.
Use of antibiotic therapy for acute conditions within 14 days prior to the Screening Visit. Low doses of antibiotics taken for prophylaxis are permitted if the therapy was started prior to the Screening Visit and is expected to continue throughout the trial.
Initiation of immunotherapy during the study period or dose escalation during the study period. However, initiation of immunotherapy 90 days or more prior to the Screening Visit and use of a stable (maintenance) dose (30 days or more) may be considered for inclusion.
Previous participation in an intranasal ciclesonide HFA nasal aerosol study.
Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding the Screening Visit.
Use of topical corticosteroids in concentrations in excess of 1% hydrocortisone or equivalent within 30 days prior to Visit 2; use of a topical hydrocortisone or equivalent in any concentration covering greater than 20% of the body surface; or presence of an underlying condition (as judged by the investigator) that can reasonably be expected to require treatment with such preparations during the course of the study.
Initiation of pimecrolimus cream 1% or greater or tacrolimus ointment 0.03% or greater during the study period or planned dose escalation during the study period. However, initiation of these creams/ointments 30 days or more prior to the Visit 1 and use of a stable (maintenance) dose during the study period may be considered for inclusion.
Study participation by clinical investigator site employees and/or their immediate relatives.
Study participation by more than one subject from the same household at the same time.
Have any of the following conditions that are judged by the investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial: impaired hepatic function including alcohol-related liver disease or cirrhosis;
- history of ocular disturbances e.g. glaucoma or posterior subcapsular cataracts;
- any systemic infection;
- hematological, hepatic, renal, endocrine (except for controlled diabetes mellitus or postmenopausal symptoms or hypothyroidism);
- gastrointestinal disease;
- malignancy (excluding basal cell carcinoma);
- current neuropsychological condition with or without drug therapy.
Any condition that, in the judgment of the investigator, would preclude the subject from completing the protocol with capture of the assessments as written.

PubMed Identifier	Type	Citation	Retractions
21130386	Result	Ratner P, Jacobs R, Mohar D, Huang H, Desai SY, Hinkle J. Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 mug once daily, for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2010 Dec;105(6):471-9. doi: 10.1016/j.anai.2010.09.024.

ID	Title	Description
FG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
FG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Categorical

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
<=18 years	BG00011 BG0018 BG00212 BG003

Age, Continuous

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	BG00041.1± 12.7 BG00142.1± 12.9 BG002

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG000159 BG001155 BG002

Race/Ethnicity, Customized

Number

participants

Title

Denominators

Categories

White/Caucasian

Title	Measurements
	BG000218 BG001220 BG002

Baseline reflective total nasal symptom score (rTNSS)

TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe. Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.

Mean

Standard Deviation

Units on a scale

Title

Denominators

Categories

Title	Measurements
	BG0009.36± 1.76 BG001

Baseline instantaneous total nasal symptom score (iTNSS)

TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe. Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.

Mean

Standard Deviation

Units on a scale

Title

Denominators

Categories

Title	Measurements
	BG0008.83± 2.03 BG001

Baseline reflective total ocular symptom score (rTOSS) in subjects with (rTOSS) ≥5.0

Total Ocular Symptom Score(TOSS) is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.

Mean

Standard Deviation

Units on a scale

Title

Denominators

Categories

Title	Measurements
	BG0006.89± 1.27 BG001

Baseline instantaneous total ocular symptom score (iTOSS) in subjects with (iTOSS) ≥5.0

TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.

Mean

Standard Deviation

Units on a scale

Title

Denominators

Categories

Title	Measurements
	BG0006.91± 1.19 BG001

Baseline reflective nasal symptom score (rNSS)

NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.

Mean

Standard Deviation

Units on a scale

Title

Denominators

Categories

AM Sneezing

Title	Measurements
	BG0002.02± 0.73 BG001

Baseline instantaneous nasal symptom score (iNSS)

NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);

= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.

Mean

Standard Deviation

Units on a scale

Title

Denominators

Categories

AM Sneezing

Title	Measurements
	BG0001.72± 0.91 BG001

Baseline individual reflective ocular symptom score (rOSS) in subjects with (rTOSS) ≥5.0

OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms).

Median

Standard Deviation

Units on a scale

Title

Denominators

Categories

AM Itching Eyes

Title	Measurements
	BG0002.48± 0.42 BG001

Baseline individual instantaneous ocular symtom score (iOSS) in subjects with (iTOSS) ≥5.0

OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms).

Mean

Standard Deviation

Units on scale

Title

Denominators

Categories

AM Itching Eyes

Title	Measurements
	BG0002.44± 0.44 BG001

Baseline Instantaneous Total Ocular Symptoms Scores (iTOSS)] for Onset of Nasal Improvement

Baseline is the last non-missing instantaneous AM assessment on or before Day 1. Onset of nasal improvement is defined as the first assessment at which instantaneous TNSS for active treatment demonstrates an improvement over placebo from baseline with one-sided p-value of <= 0.025.

Mean

Standard Deviation

Hours

Title

Denominators

Categories

Title	Measurements
	BG0006.85± 1.72 BG001

Baseline Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in subject with RQLQ(S) score ≥3.

RQLQ(S)consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.

Mean

Standard Deviation

units on a scale

Title

Denominators

Categories

Title	Measurements
	BG0004.52± 0.77 BG001

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG000109 BG001102 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Change From Baseline in Daily Subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Averaged Over the Two-week Treatment Period.

TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Intent to treat population.

Posted

Least Squares Mean

Standard Error

units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts
Participants	OG000237 OG001234 OG002234

Title

Denominators

Categories

Title	Measurements
	OG000-1.45± 0.14 OG001-1.59± 0.14 OG002-0.51± 0.14

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG002	The null hypothesis is that there is no difference in primary outcome when compare active to placebo group. The alternative hypothesis is that there is a difference in primary outcome when compare active to placebo group. It was estimated that 200 subjects per group will provide at least 85% power to detect a difference between treatment groups of 0.7 in the change from baseline in rTNSS with a two-sided alpha level of 0.025.	ANCOVA		<0.0001	The p-value from primary outcome was adjusted at alpha=0.025.	Mean Difference (Final Values)	0.94			2-Sided	95	0.57	1.32				No	Superiority or Other

Secondary

Change From Baseline in Daily Subject-reported AM and PM iTNSS Averaged Over the Two-week Treatment Period.

TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Intent to treat population

Posted

Least Squares Mean

Standard Error

units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported AM and PM rTOSS Averaged Over the Two-week Treatment Period in Participants With a Baseline rTOSS >= 5.0

TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Intent to treat population. In participants with a baseline rTOSS >= 5.0

Posted

Least Squares Mean

Standard Error

units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported AM rTNSS Averaged Over the Two Week Treatment Period

TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Jan 2011

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported PM rTNSS Averaged Over the Two Week Treatment Period

TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Jan 2011

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported AM iTNSS Averaged Over the Two Week Treatment Period

TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Jan 2011

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported PM iTNSS Averaged Over the Two Week Treatment Period

TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported AM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0

TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline rTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported PM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0

TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline rTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported AM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0

TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline iTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0

TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline iTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject Reported AM and PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0

TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline iTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported AM rNSS Averaged Over the Two Week Treatment Period

NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported PM rNSS Averaged Over the Two Week Treatment Period

NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported AM and PM rNSS Averaged Over the Two Week Treatment Period

NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported AM iNSS Averaged Over the Two Week Treatment Period

NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported PM iNSS Averaged Over the Two Week Treatment Period

NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported AM and PM iNSS Averaged Over the Two Week Treatment Period

NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Units	Counts

Secondary

Change From Baseline in Daily Subject-reported AM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0

OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline rTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0

OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline rTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported and AM and PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0

OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline rTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported AM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0

OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline iTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0

OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline iTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Daily Subject-reported AM and PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0

OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.

In Subjects With Baseline iTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Change From Baseline in Overall Score of the Rhinoconjunctivitis Quality of Life Questionnaire With Standard Activities (RQLQ(S)) in Participants With a Baseline Overall Score >= 3.0

The RQLQ(S) in impaired subjects (baseline RQLQ[S] score ≥3.0) at baseline and end of week 2. It consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.

In participants with a Baseline overall score >= 3.0

Posted

Least Squares Mean

Standard Error

units on a scale

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Onset of Improvement in Instantaneous Total Nasal Symptoms Scores (iTNSS)

Onset of nasal improvement was defined as the first assessment at which iTNSS for active treatment demonstrated an improvement over placebo from baseline.

TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent, 1 = mild, 2 = moderate, 3 = severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and 12 reflecting more severe symptoms). Instaneous measures these symptoms over the previous 10 minute time interval.

Intent to Treat Population. Some participants excluded for missing data.

Posted

Least Squares Mean

Standard Error

Units on a scale

Baseline and up to 36 hours

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo

Units	Counts

Secondary

Onset of Improvement in Instantaneous Total Ocular Symptoms Scores (iTOSS) in Subjects With Baseline iTOSS ≥5.0

Onset of improvement iTOSS was defined as the first assessment at which iTOSSS for active treatment demonstrated an improvement over placebo from baseline. TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

0 = absent

= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval.

In Subjects With Baseline iTOSS ≥5.0

Posted

Least Squares Mean

Standard Error

Units on a scale

Baseline and up to 48 hours

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
OG002	Placebo	Placebo once daily

Secondary

Time to Maximal Effect as Measured by Change From Baseline in the Average AM and PM Reflective Total Nasal Symptoms Scores (rTNSS)

The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between Ciclesonide HFA and placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day.

Intent to Treat Population

Posted

Least Squares Mean

Standard Error

days

Week 0-2

ID	Title	Description
OG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
OG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily

Units	Counts
Participants	OG000

Facility	Status	City	State	ZIP	Country	Contacts
		Austin	Texas	78731	United States

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Epistaxis	Respiratory, thoracic and mediastinal disorders	MedDRA (11.1)	Systematic Assessment	EG0009 events8 affected237 at risk EG0017 events5 affected235 at risk EG00211 events10 affected235 at risk
Nasal discomort	Respiratory, thoracic and mediastinal disorders	MedDRA (11.1)	Systematic Assessment	EG0005 events5 affected237 at risk EG0015 events5 affected235 at risk EG0027 events7 affected235 at risk
Nasal septum disorder	Respiratory, thoracic and mediastinal disorders	MedDRA (11.1)	Systematic Assessment	EG0005 events5 affected237 at risk EG0011 events1 affected235 at risk EG0023 events3 affected235 at risk
Instillation site irritation	General disorders	MedDRA (11.1)	Systematic Assessment	EG0005 events5 affected237 at risk EG0013 events3 affected235 at risk EG0022 events2 affected235 at risk

ID	Term
D065631	Rhinitis, Allergic
D012220	Rhinitis
D009668	Nose Diseases
D012140	Respiratory Tract Diseases
D012130	Respiratory Hypersensitivity
D010038	Otorhinolaryngologic Diseases
D006969	Hypersensitivity, Immediate
D006967	Hypersensitivity
D007154	Immune System Diseases

ID	Title	Description
BG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily
BG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily
BG002	Placebo	Placebo once daily
BG003	Total	Total of all reporting groups

ID	Title	Description	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	80 mcg Ciclesonide	80 mcg Ciclesonide once daily	0	237	21	237
EG001	160 mcg Ciclesonide	160 mcg Ciclesonide once daily	1	235	14	235
EG002	Placebo	Placebo once daily	0	235	22	235